The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The role of stromal cells and the tumour microenvironment in general in modulating tumour sensitivity is increasingly becoming a key consideration for the development of active anticancer therapeutics. Here, we discuss how these tumour-stromal interactions affect tumour cell signalling, survival, proliferation and drug sensitivity. Particular emphasis is placed on the ability of stromal cells to confer - to tumour cells - resistance or sensitization to different classes of therapeutics, depending on the specific microenvironmental context. The mechanistic understanding of these microenvironmental interactions can influence the evaluation and selection of candidate agents for various cancers, in both the primary site as well as the metastatic setting. Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy. These recent advances can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“Hence, tumor-stromal interactions, the composition of the TME and tumor immune status all contribute to determining tumor growth, metastasis, angiogenesis and therapy resistance (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021), thereby critically influencing the clinical outcome of cancer patients.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“In addition, many studies have highlighted the critical importance of the microenvironment for promoting or suppressing tumor growth, invasion, metastasis, and response to therapy (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“The non‐malignant cells and matrixcomponents which make up the TME have been shown to playa role in tumor cell survival, proliferation,andtreatment resistance (48).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [48]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Self-citationBortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Tumor metastasis: mechanistic insights and clinical challenges
Steeg, P. S. (2006) · Nature Medicine · doi:10.1038/nm1469 · Cited by 2,134
Debnath, J., Muthuswamy, S. K., & Brugge, J. S. (2003) · Methods · doi:10.1016/s1046-2023(03)00032-x · Cited by 1,995
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Bissell, M. J., & Hines, W. C. (2011) · Nature Medicine · doi:10.1038/nm.2328 · Cited by 1,517
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature Reviews Immunology · doi:10.1038/nri2017 · Cited by 1,279
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Humanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
The diverse and complex roles of NF-κB subunits in cancer
Perkins, N. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3204 · Cited by 852
Paraneoplastic thrombocytosis in ovarian cancer
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110352 · Cited by 812
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Shi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R. C., Ng, C., Chodon, T., Scolyer, R. A., Dahlman, K. B., et al. (2012) · Nature Communications · doi:10.1038/ncomms1727 · Cited by 640
Balkwill, F., & Coussens, L. M. (2004) · Nature · doi:10.1038/431405a · Cited by 627
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Self-citationThe organizing principle: microenvironmental influences in the normal and malignant breast
Bissell, M. J., Radisky, D. C., Rizki, A., Weaver, V. M., & Petersen, O. W. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700907.x · Cited by 605
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585
Self-citationThe anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 566
Mutations in the NF-κB signaling pathway: implications for human disease
Courtois, G., & Gilmore, T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209939 · Cited by 525
Distinct epigenetic changes in the stromal cells of breast cancers
Hu, M., Yao, J., Cai, L., Bachman, K. E., van den Brûle, F., Velculescu, V., & Polyak, K. (2005) · Nature Genetics · doi:10.1038/ng1596 · Cited by 520
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9223-6 · Cited by 515
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111840108 · Cited by 477
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Cheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423
Role of organ selectivity in the determination of metastatic patterns of B16 melanoma.
Hart, I. R., & Fidler, I. J. (1980) · PubMed · Cited by 423
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
The microenvironment in breast cancer progression: biology and implications for treatment
Place, A. E., Jin Huh, S., & Polyak, K. (2011) · Breast Cancer Research · doi:10.1186/bcr2912 · Cited by 413
Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
Mouse models of advanced spontaneous metastasis for experimental therapeutics
Francia, G., Cruz-Munoz, W., Man, S., Xu, P., & Kerbel, R. S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3001 · Cited by 374
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcia-Prieto, C., Lu, W., Burger, J. A., Croce, C. M., Plunkett, W., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2432 · Cited by 357
Current advances in humanized mouse models
Ito, R., Takahashi, T., Katano, I., & Ito, M. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.2 · Cited by 349
Economics of New Oncology Drug Development
DiMasi, J. A., & Grabowski, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0803 · Cited by 348
Implantation mechanisms: insights from the sheep
Spencer, T. E., Johnson, G. A., Bazer, F. W., & Burghardt, R. C. (2004) · Reproduction · doi:10.1530/rep.1.00398 · Cited by 344
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
Teicher, B., Herman, T., Holden, S., Wang, Y., Pfeffer, M., Crawford, J., & Frei, E. (1990) · Science · doi:10.1126/science.247.4949.1457 · Cited by 327
Cancer and Inflammation: Promise for Biologic Therapy
Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y.-C., El-Omar, E. M., Trinchieri, G., Dubinett, S. M., Mao, J. T., Szabo, E., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32e74 · Cited by 325
Immune microenvironments in solid tumors: new targets for therapy
Shiao, S. L., Ganesan, A. P., Rugo, H. S., & Coussens, L. M. (2011) · Genes & Development · doi:10.1101/gad.169029.111 · Cited by 322
Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Nagaiah, G., Hossain, A., Mooney, C. J., Parmentier, J., & Remick, S. C. (2011) · Journal of Oncology · doi:10.1155/2011/542358 · Cited by 317
McMillin, D. W., Delmore, J., Weisberg, E., Negri, J. M., Geer, D. C., Klippel, S., Mitsiades, N., Schlossman, R. L., Munshi, N. C., Kung, A. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2112 · Cited by 315
Self-citationDoes tumour dormancy offer a therapeutic target?
Goss, P. E., & Chambers, A. F. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2933 · Cited by 302
BISSELL, M. J., KENNY, P. A., & RADISKY, D. C. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.013 · Cited by 298
The State of Innovation in Drug Development
Kola, I. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100479 · Cited by 276
Integrins: The Keys to Unlocking Angiogenesis
Silva, R., D'Amico, G., Hodivala-Dilke, K. M., & Reynolds, L. E. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.172015 · Cited by 255
Nefedova, Y., Landowski, T. H., & Dalton, W. S. (2003) · Leukemia · doi:10.1038/sj.leu.2402924 · Cited by 248
The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
Li, N., Grivennikov, S. I., & Karin, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.018 · Cited by 245
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Chan, N., Pires, I. M., Bencokova, Z., Coackley, C., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2352 · Cited by 244
Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2377 · Cited by 243
Functional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima, M., Howie, H. L., Imakura, M., Walsh, R. M., Annis, J. E., Chang, A. N., Frazier, J., Chau, B. N., Loboda, A., Linsley, P. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121119109 · Cited by 242
'Role of bone marrow stromal cells in the growth of human multiple myeloma
Caligaris-Cappio, F., Bergui, L., Gregoretti, M., Gaidano, G., Gaboli, M., Schena, M., Zallone, A., & Marchisio, P. (1991) · Blood · doi:10.1182/blood.v77.12.2688.2688 · Cited by 234
Wounding and Its Role in RSV-Mediated Tumor Formation
Dolberg, D. S., Hollingsworth, R., Hertle, M., & Bissell, M. J. (1985) · Science · doi:10.1126/science.2996144 · Cited by 230
Chesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., Stewart, A. K., Johnstone, R. W., & Bergsagel, P. L. (2012) · Blood · doi:10.1182/blood-2012-02-412783 · Cited by 214
A Mouse Model of Human Breast Cancer Metastasis to Human Bone
Kuperwasser, C., Dessain, S., Bierbaum, B. E., Garnet, D., Sperandio, K., Gauvin, G. P., Naber, S. P., Weinberg, R. A., & Rosenblatt, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1408 · Cited by 212
Dumont, N., Wilson, M. B., Crawford, Y. G., Reynolds, P. A., Sigaroudinia, M., & Tlsty, T. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807146105 · Cited by 210
The metastatic niche and stromal progression
Sleeman, J. P. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9373-9 · Cited by 203
Hung, K. E., Maricevich, M. A., Richard, L. G., Chen, W. Y., Richardson, M. P., Kunin, A., Bronson, R. T., Mahmood, U., & Kucherlapati, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908682107 · Cited by 198
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim, A., Scher, N. S., Williams, G., Sridhara, R., Li, N., Chen, G., Leighton, J. C., Booth, B. P., Gobburu, J. V. S., Rahman, A., et al. (2003) · PubMed · Cited by 196
Generation of phenotypic diversity and progression in metastatic tumor cells
Nicolson, G. L. (1984) · Cancer and Metastasis Review · doi:10.1007/bf00047691 · Cited by 180
Bhatia, R., McGlave, P., Dewald, G., Blazar, B., & Verfaillie, C. (1995) · Blood · doi:10.1182/blood.v85.12.3636.bloodjournal85123636 · Cited by 178
Jorcyk, C. L., Tawara, K., & Jorcyk, C. L. (2011) · Cancer Management and Research · doi:10.2147/cmr.s18101 · Cited by 176
Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment.
Denko, N. C., Schindler, C., Koong, A. C., Laderoute, K. R., Green, C., & Giaccia, A. J. (2000) · Clinical Cancer Research · Cited by 175
Peyruchaud, O., Winding, B., Pécheur, I., Serre, C.-M., Delmas, P., & Clézardin, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.11.2027 · Cited by 173
Examining the Metastatic Niche: Targeting the Microenvironment
Guise, T. A. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.007 · Cited by 168
Modulation of tumor cell response to chemotherapy by the organ environment
Fidler, I. J., Wilmanns, C., Staroselsky, A., Radinsky, R., Dong, Z., & Fan, D. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689637 · Cited by 165
Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance
Flach, E. H., Rebecca, V. W., Herlyn, M., Smalley, K. S. M., & Anderson, A. R. A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200421k · Cited by 156
Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0314 · Cited by 150
Characterization of adhesion molecules on human myeloma cell lines
Uchiyama, H., Barut, B., Chauhan, D., Cannistra, S., & Anderson, K. C. (1992) · Blood · doi:10.1182/blood.v80.9.2306.2306 · Cited by 146
Stassi, G., Todaro, M., Zerilli, M., Ricci‐Vitiani, L., Liberto, D. D., Patti, M., Florena, A., Gaudio, F. D., Gesù, G. D., & Maria, R. D. (2003) · PubMed · Cited by 144
Schmidt, T., Masouleh, B. K., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., Jonckx, B., Keersmaecker, K. D., Kleppe, M., Tjwa, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.007 · Cited by 140
Development of a Preclinical Model of Spontaneous Human Melanoma Central Nervous System Metastasis
Cruz‐Muñoz, W., Man, S., Xu, P., & Kerbel, R. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0041 · Cited by 140
Revisiting the seed and soil in cancer metastasis
Mendoza, M., & Khanna, C. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.01.015 · Cited by 139
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, T. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799014968 · Cited by 138
Groen, R. W. J., Noort, W. A., Raymakers, R. A. P., Prins, H., Aalders, L., Hofhuis, F. M., Moerer, P., van Velzen, J. F., Bloem, A. C., van Kessel, B., et al. (2012) · Blood · doi:10.1182/blood-2012-03-414920 · Cited by 135
Recent advances in non-small cell lung cancer biology and clinical management.
Saintigny, P., & Burger, J. A. (2012) · PubMed · Cited by 129
Martins‐Green, M. M., Boudreau, N. J., & Bissell, M. J. (1994) · PubMed · Cited by 120
Stubbs, M. C., Kim, Y., Krivtsov, A. V., Wright, R. D., Feng, Z., Agarwal, J., Kung, A. L., & Armstrong, S. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404951 · Cited by 117
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
Singh, M., & Ferrara, N. (2012) · Nature Biotechnology · doi:10.1038/nbt.2286 · Cited by 114
Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis
Lynch, C. C. (2010) · Bone · doi:10.1016/j.bone.2010.06.007 · Cited by 108
Smith, S. C., Baras, A. S., Lee, J. K., & Theodorescu, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3562 · Cited by 108
Manshouri, T., Estrov, Z. E., Quintás‐Cardama, A., Burger, J. A., Zhang, Y., Livun, A., Knez, L., Harris, D., Creighton, C. J., Kantarjian, H. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4002 · Cited by 106
Brigger, I., Morizet, J., Laudani, L., Aubert, G., Appel, M., Velasco, V., Terrier-Lacombe, M.-J., Desmaële, D., d’Angelo, J., Couvreur, P., et al. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.019 · Cited by 101
The Tumor-Promoting Effect of Wounding: A Possible Role for TGF-β-lnduced Stromal Alterations
Sieweke, M. H., & Bissell, M. J. (1994) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v5.i2-3.90 · Cited by 99
Genomically humanized mice: technologies and promises
Devoy, A., Bunton-Stasyshyn, R. K. A., Tybulewicz, V. L. J., Smith, A. J. H., & Fisher, E. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3116 · Cited by 98
Pillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 91
Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases
Hoffmann, J., Fichtner, I., Lemm, M., Lienau, P., Hess‐Stumpp, H., Rotgeri, A., Hofmann, B., & Klar, U. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-072 · Cited by 83
Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors
McCullough, K. D., Coleman, W. B., Ricketts, S. L., Wilson, J. W., Smith, G. J., & Grisham, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15333 · Cited by 79
Weisberg, E., Kung, A. L., Wright, R. D., Moreno, D., Catley, L., Ray, A., Zawel, L. S., Tran, M., Cools, J., Gilliland, G. D., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0810 · Cited by 79
Self-citationTranslational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.
Zitvogel, L., & Kroemer, G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39991 · Cited by 76
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I. M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4053 · Cited by 75
Hudes, G., Tagawa, S., Whang, Y., Qi, M., Qin, X., Puchalski, T., Reddy, M., Cornfeld, M., & Eisenberger, M. (2013) · Investigational new drugs · doi:10.1007/s10637-012-9857-z · Cited by 71
Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
Tefferi, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1115119 · Cited by 67
Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Dijkgraaf, E. M., Welters, M. J. P., Nortier, J. W. R., van der Burg, S. H., & Kroep, J. R. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802002797 · Cited by 64
Tabe, Y., Jin, L., Iwabuchi, K., Wang, R.-Y., Ichikawa, N., Miida, T., Cortes, J. E., Andreeff, M., & Konopleva, M. Y. (2011) · Leukemia · doi:10.1038/leu.2011.291 · Cited by 59
Chrenek, M. A., Wong, P., & Weaver, V. M. (2001) · Breast Cancer Research · doi:10.1186/bcr300 · Cited by 59
Evaluation of the cocarcinogenic effect of wounding in Rous sarcoma virus tumorigenesis.
Sieweke, M. H., Stoker, A. W., & Bissell, M. J. (1989) · PubMed · Cited by 55
Dudley, A. C., Shih, S.-C., Cliffe, A. R., Hida, K., & Klagsbrun, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604465 · Cited by 53
Wilson, C., Holen, I., & Coleman, R. E. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.007 · Cited by 48
Kadoch, C., Dinca, E. B., Voicu, R., Chen, L., Nguyen, D., Parikh, S., Karrim, J., Shuman, M. A., Lowell, C. A., TRESELER, P. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2054 · Cited by 40
Macanas-Pirard, P., Leisewitz, A. V., Broekhuizen, R., Cautivo, K. M., Barriga, F. M., Leisewitz, F., Gidi, V., Riquelme, E. M., Montecinos, V. P., Swett, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037203 · Cited by 39
Influence of microenvironmental pH on adriamycin resistance.
Alabaster, O., Woods, T., Ortiz-Sanchez, V., & Jahangeer, S. M. (1989) · PubMed · Cited by 35
McMillin, D. W., Delmore, J. E., Negri, J. M., Vanneman, M. W., Koyama, S., Schlossman, R. L., Munshi, N. C., Laubach, J. P., Richardson, P. G. G., Dranoff, G., et al. (2012) · Blood · doi:10.1182/blood-2011-04-348490 · Cited by 35
Self-citationNew drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
Curigliano, G. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.006 · Cited by 33
New druggable targets in the Ras pathway?
Matallanas, D., & Crespo, P. (2010) · PubMed · Cited by 32
Emmons, M. F., Gebhard, A. W., Nair, R. R., Baz, R., McLaughlin, M. L., Cress, A. E., & Hazlehurst, L. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0149 · Cited by 29
McMillin, D. W., Delmore, J. E., Negri, J. M., Ooi, M. G. M., Klippel, S., Miduturu, C. V., Gray, N. S., Richardson, P. G. G., Anderson, K. C., Kung, A. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020226 · Cited by 27
Self-citationIn vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465
Negri, J. M., McMillin, D. W., Delmore, J. E., Mitsiades, N., Hayden, P. J., Klippel, S., Hideshima, T., Chauhan, D., Munshi, N. C., Buser, C. A., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07891.x · Cited by 27
Self-citationCruickshanks, N. A., Hamed, H. A., Bareford, M. D., Poklepovic, A. S., Fisher, P. B., Grant, S., & Dent, P. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.077586 · Cited by 24
Moshaver, B., van der Pol, M. A., Westra, A. H., Ossenkoppele, G. J., Zweegman, S., & Schuurhuis, G. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701593636 · Cited by 23
Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes
Kastrinaki, M.-C., Pontikoglou, C. G., Klaus, M., Stavroulaki, E., Pavlaki, K. I., & Papadaki, H. Α. (2011) · Current Stem Cell Research & Therapy · doi:10.2174/157488811795495422 · Cited by 23
Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation
Gomes, R. R., Buttke, P., Paul, E. M., & Sikes, R. A. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9263-x · Cited by 21
Guo-bao, W., Chen, X., Qi-Rong, G., Jie, L., Gui-Nan, L., & Lu, Y. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003746315 · Cited by 20
Third-Generation Tyrosine Kinase Inhibitors and Beyond
Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.06.004 · Cited by 19
Brama, M., Basciani, S., Cherubini, S., Mariani, S., Migliaccio, S., Arizzi, M., Rosano, G. M. C., Spera, G., & Gnessi, L. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01307 · Cited by 19
Role of VAD in the initial treatment of multiple myeloma
Lane, S., Gill, D. S., & Mollee, P. N. (2005) · Blood · doi:10.1182/blood-2005-07-2610 · Cited by 16
How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection
Scielzo, C., ten Hacken, E., Bertilaccio, M. T. S., Muzio, M., Calissano, C., Ghia, P., & Caligaris‐Cappio, F. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.505061 · Cited by 16
Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Weisberg, E., Choi, H. G., Barrett, R., Zhou, W., Zhang, J., Ray, A., Nelson, E. A., Jiang, J., Moreno, D., Stone, R. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0232 · Cited by 16
Histamine restricts cancer: nothing to sneeze at
Ruffell, B., & Coussens, L. M. (2011) · Nature Medicine · doi:10.1038/nm0111-43 · Cited by 15
Liang, X., Hao, L., Chen, X., Zhang, X., Kong, P., Peng, X., Gao, L., Zhang, C., & Wang, Q. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.08.055 · Cited by 7
McCarthy, N. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2743 · Cited by 2
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
“…altered local drug availability, by affecting expression of drug targets, or by changing intrinsic cellular defense mechanisms such as increased repair upon DNA damage or evasion of apoptosis (Sebens and Schafer, 2012; Junttila and de Sauvage, 2013; McMillin et al., 2013; Holle et al., 2016).”
BackgroundAngiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review
Azmi, A. S., Bao, B., & Sarkar, F. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9441-9 · Cited by 1,167
“The development of resistance is multifactorial that includes switching of cancer cells to secondary salvage pathways when the primary hallmark is shut [133], epigenetic suppression of tumor suppressor protein activation by miRNAs [134], presence of a subpopulation of highly resistant cancer stem-like cells with enhan…”
Metadata
- Authors
- McMillin, D. W., Negri, J. M., & Mitsiades, C. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Corresponding author
- Mitsiades, Constantine S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03
- Volume
- 12
- Issue
- 3
- Pages
- 217-228
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1980669422
- Cited by
- 474
- References
- 150
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 27 · 2023: 34 · 2022: 29 · 2021: 43 · 2020: 41 · 2019: 33 · 2018: 49 · 2017: 56 · 2016: 41 · 2015: 40 · 2014: 27 · 2013: 16
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R0-1 50947)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- tumor microenvironment, stromal cells, drug resistance, drug sensitivity, anticancer drug discovery, preclinical models, orthotopic xenograft, metastasis
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Drug Screening Assays, Antitumor, Humans, Neoplasms, Stromal Cells, Drug Resistance, Neoplasm, Drug Discovery, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.